Regency Therapeutics

Regency Therapeutics was a biotechnology company focused on developing first-in-class small molecule therapeutics for neurological and psychiatric disorders. The company's primary focus was on the discovery of Potassium-chloride cotransporter 2 (KCC2) activators to restore inhibitory signaling in the central nervous system. Its lead programs targeted indications such as neuropathic pain and epilepsy, where KCC2 downregulation is a known pathological driver. Regency was founded based on research from the University of Toronto and the Hospital for Sick Children (SickKids) and was eventually acquired by Aptinyx to integrate its KCC2 portfolio.